Overview

Description

  • Nature
    Synthetic

Associated products

Specifications

Our Abpromise guarantee covers the use of ab42682 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

  • Applications

    Blocking - Blocking peptide for Anti-EAAT1 antibody (ab41751)

  • Form
    Liquid
  • Additional notes

    - First try to dissolve a small amount of peptide in either water or buffer. The more charged residues on a peptide, the more soluble it is in aqueous solutions.
    - If the peptide doesn’t dissolve try an organic solvent e.g. DMSO, then dilute using water or buffer.
    - Consider that any solvent used must be compatible with your assay. If a peptide does not dissolve and you need to recover it, lyophilise to remove the solvent.
    - Gentle warming and sonication can effectively aid peptide solubilisation. If the solution is cloudy or has gelled the peptide may be in suspension rather than solubilised.
    - Peptides containing cysteine are easily oxidised, so should be prepared in solution just prior to use.

  • Concentration information loading...

Preparation and Storage

  • Stability and Storage

    Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

    Information available upon request.

General Info

  • Alternative names
    • EA6
    • EAA1_HUMAN
    • EAAT1
    • Excitatory amino acid transporter 1
    • FLJ25094
    • GLAST
    • GLAST-1
    • GLAST1
    • Glial high affinity glutamate transporter
    • glutamate/aspartate transporter, high affinity, sodium-dependent
    • High affinity neuronal glutamate transporter
    • Slc1a3
    • Sodium dependent glutamate/aspartate transporter
    • Sodium-dependent glutamate/aspartate transporter 1
    • Solute carrier family 1 (glial high affinity glutamate transporter) member 3
    • Solute carrier family 1 member 3
    see all
  • Function
    Transports L-glutamate and also L- and D-aspartate. Essential for terminating the postsynaptic action of glutamate by rapidly removing released glutamate from the synaptic cleft. Acts as a symport by cotransporting sodium.
  • Tissue specificity
    Highly expressed in cerebellum, but also found in frontal cortex, hippocampus and basal ganglia.
  • Involvement in disease
    Defects in SLC1A3 are the cause of episodic ataxia type 6 (EA6) [MIM:612656]. EA6 is characterized by episodic ataxia, seizures, migraine and alternating hemiplegia.
  • Sequence similarities
    Belongs to the sodium:dicarboxylate (SDF) symporter (TC 2.A.23) family. SLC1A3 subfamily.
  • Post-translational
    modifications
    Glycosylated.
  • Cellular localization
    Membrane.
  • Information by UniProt

References

ab42682 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

Thank you for contacting us.

Unfortunately the blocking peptide is not available so I am sorry we are unable to with this inquiry.

I hope this information is nevertheless helpful to you. Please do not hesitate to contact us if you nee...

Read More

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up